Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CFO Mark Ragosa Sells 11,464 Shares of Stock

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) CFO Mark Ragosa sold 11,464 shares of the company's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $23.10, for a total transaction of $264,818.40. Following the sale, the chief financial officer now directly owns 23,382 shares of the company's stock, valued at approximately $540,124.20. This trade represents a 32.90 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Mark Ragosa also recently made the following trade(s):

• On Wednesday, March 19th, Mark Ragosa sold 8,879 shares of Kiniksa Pharmaceuticals stock. The shares were sold at an average price of $23.10, for a total value of $205,104.90.
• On Wednesday, March 12th, Mark Ragosa sold 36,372 shares of Kiniksa Pharmaceuticals stock. The stock was sold at an average price of $22.25, for a total value of $809,277.00.

Kiniksa Pharmaceuticals Stock Performance

Shares of NASDAQ:KNSA traded down $0.45 during midday trading on Friday, hitting $23.36. 435,145 shares of the stock were exchanged, compared to its average volume of 406,548. The business's 50-day moving average price is $20.30 and its 200 day moving average price is $22.04. The stock has a market capitalization of $1.70 billion, a price-to-earnings ratio of -166.85 and a beta of 0.48. Kiniksa Pharmaceuticals, Ltd. has a 12 month low of $16.56 and a 12 month high of $28.15.

Remove Ads

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last posted its earnings results on Tuesday, February 25th. The company reported ($0.12) earnings per share for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.06). The business had revenue of $122.50 million for the quarter, compared to the consensus estimate of $123.42 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The company's revenue was up 46.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.35 earnings per share. As a group, sell-side analysts expect that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current year.

Institutional Trading of Kiniksa Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Teacher Retirement System of Texas grew its position in shares of Kiniksa Pharmaceuticals by 7.1% in the 4th quarter. Teacher Retirement System of Texas now owns 10,862 shares of the company's stock valued at $215,000 after buying an additional 719 shares during the last quarter. Martingale Asset Management L P lifted its stake in shares of Kiniksa Pharmaceuticals by 1.9% in the fourth quarter. Martingale Asset Management L P now owns 49,360 shares of the company's stock worth $976,000 after acquiring an additional 900 shares during the period. China Universal Asset Management Co. Ltd. boosted its holdings in Kiniksa Pharmaceuticals by 12.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,814 shares of the company's stock valued at $174,000 after acquiring an additional 1,004 shares during the last quarter. Franklin Resources Inc. increased its position in Kiniksa Pharmaceuticals by 1.7% during the 3rd quarter. Franklin Resources Inc. now owns 67,533 shares of the company's stock valued at $1,798,000 after purchasing an additional 1,100 shares during the period. Finally, MetLife Investment Management LLC raised its holdings in Kiniksa Pharmaceuticals by 6.3% during the 4th quarter. MetLife Investment Management LLC now owns 23,095 shares of the company's stock worth $457,000 after purchasing an additional 1,374 shares during the last quarter. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have commented on KNSA shares. Wedbush reissued an "outperform" rating and set a $34.00 target price on shares of Kiniksa Pharmaceuticals in a research note on Tuesday, February 25th. Citigroup started coverage on shares of Kiniksa Pharmaceuticals in a report on Thursday, March 13th. They set a "buy" rating and a $40.00 price target on the stock. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $37.17.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.